Canadian Cancer Trials Group MA.27
|Final results of Canadian Cancer Trials Group MA.27 -- A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer -- indicate that exemestane and anastrozole provide similar control of breast cancer and survival and may have different side effect profiles. Exemestane, therefore, may be considered as an alternative, first-line adjuvant therapy.
These results were presented by Dr. Paul Goss, chair of the MA.27 trial committee, at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) on Thursday, 9 December 2010.
MA.27 was selected by the SABCS organizers to be highlighted in a press release. This release can be viewed using this link ... http://aacr.pr-optout.com/ViewAttachment.aspx?EID=K6ituFshGjFZW%2bYTy3w0Fw7HKL6CmdUBqbxxiIB7Sx4%3d.
In total, 7,576 women from Canada, the United States and Europe were enrolled onto MA.27. The trial included support from the U.S. National Cancer Institute's Cancer Therapy Evaluation Program and the European-based International Breast Cancer Study Group.
Other trial committee members included:
Kathleen I. Pritchard, Canadian Cancer Trials Group Co-Chair
James Ingle, NCCTG Co-Chair
Matthew J. Ellis, CALGB Co-Chair
George W. Sledge, ECOG Co-Chair
G. Thomas Budd, SWOG Co-Chair
Manuela Rabaglio, IBCSG Co-Chair
At Central Office, the trial was supported directly by:
Lois Shepherd, Physician Coordinator
Judy-Anne Chapman, Biostatistician
Catherine Elliott, Study Coordinator
Jessica Kundapur, Study Coordinator
In addition, many others at Central Office and elsewhere made substantial contributions to the successful completion and presentation of this study.
We would also like to thank all of the centres for their participation and commitment to this trial.
In a future Bulletin, we will be providing more detailed results.